Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dynogen Pharmaceuticals Inc.

This article was originally published in Start Up

Executive Summary

Dynogen Pharmaceuticals Inc. is focusing on the neurological underpinnings of large, undermet GU and GI disorders including overactive bladder and irritable bowel syndrome. It is in-licensing clinical-stage compounds originally earmarked for CNS indications and developing them instead to modulate neurological targets involved in GU and GI function.
Advertisement

Related Content

Exploiting Connections and Navigating Bumps Along the Brain-Gut Axis
Exploiting Connections and Navigating Bumps Along the Brain-Gut Axis

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC090764

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel